Log in to search using one of your social media accounts:

 

Pfizer's Xeljanz meets goals in ulcerative colitis trials

(Reuters) - Pfizer Inc said on Friday its Xeljanz rheumatoid arthritis drug succeeded in meeting primary and secondary goals of a pair of late stage clinical trials in ulcerative colitis, results that could help pave the way for an additional approval for the oral medicine.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

We report the case of a 68-year-old man with Crohn's disease, who developed  disseminated tuberculosis due to anti-TNF-α immunosuppressive therapy. The diagnosis was based on the histopathological findings and molecular biology assays.We discuss the clinical presentation and workup of this case, and we present a comparative analysis of tuberculosis cases associated with anti-TNF-α reported in Colombia during the last 10 years emphasizing on the diagnosis and treatment of latent tuberculosis. PMID: 29668128 [PubMed - in process]
Source: Biomedica : Revista del Instituto Nacional de Salud - Category: International Medicine & Public Health Tags: Biomedica Source Type: research
In this study, we investigated the effect of emodin on dextran sodium sulfate (DSS)-induced ulcerative colitis in mice. Our results showed that emodin significantly alleviated the symptoms of DSS-induced UC in mice, involving prevented the loss of body weight and colon shortening, decreased the disease activity index (DAI), intestinal damages and the count of white blood cells (WBC) in peripheral blood. In addition, emodin treatment decreased the level of anti-flagellin antibody in serum and significantly down-regulated the expression of TLR5 and NF-κB p65 in colon of the UC mice. Further study in vitro showed that e...
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Tags: Int Immunopharmacol Source Type: research
Your body can heal itself, which is pretty miraculous when you sit back and think about it. If you suffer a cut or infection—or if a disease, allergen or virus finds its way into you—your immune system reacts by sending specialized white blood cells to the affected area. These white blood cells can repair damage, stop the spread of infection or illness and in some cases eradicate the intruder. This whole response is called inflammation. “Inflammation is an activation of cells and cell-derived components that have the job of fighting invasions, and in some cases just sponging up or clearing out damaged cel...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized healthytime medicine Source Type: news
The committee favors marketing the infliximab biosimilar product Zessly for treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news
CONCLUSION: Five derivatives were found to be active. Compound 5 was found to be the most potent inhibitor of ROS and NO compared to parent diclofenac 1 and standard drugs ibuprofen and L-NMMA, respectively. The most active compounds 1, 4, 5, 11 and 20 were found to be non-toxic on NIH-3T3 cells. Compound 4, 5, and 20 also showed good antiinflammatory potential, compound 11 and 16 showed moderate and low level of inhibition, respectively. PMID: 29564980 [PubMed - as supplied by publisher]
Source: Medicinal Chemistry - Category: Chemistry Authors: Tags: Med Chem Source Type: research
Pfizer scored a win in its efforts to move forward a delayed application for new use of its rheumatoid arthritis drug for treating chronic inflammation of the colon.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Authors: Baričević D, Popović Grle S, Morović Vergles J, Čuković Čavka S, Jakopović M, Redžepi G, Boras Z, Baričević M, Samaržija M Abstract The aim of this study was to investigate the role of the QuantiFERON-TB Gold In-Tube test (QFT-GIT) in detecting latent tuberculosis in immunocompromised patients before introducing tumor necrosis factor (TNF-α) antagonists. The study included 300 subjects of similar age. The study group comprised of 150 QuantiFERON (QFT) positive subjects with rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and psoriatic arthritis, while con...
Source: Acta Clinica Croatica - Category: General Medicine Tags: Acta Clin Croat Source Type: research
AbstractPurpose of ReviewMonoclonal antibodies targeting tumor necrosis factor-alpha, integrin molecules, and interleukin-12/23 have become backbone therapies for Crohn ’s disease and ulcerative colitis. While clinically effective, these biologic therapies come with significant expense, contributing to overall healthcare spending in the USA. Biosimilars have the potential to significantly reduce expenditures secondary to the use of biologic medications such as in fliximab and adalimumab, though their complicated manufacturing process results in inherent differences in structure when compared to the originator compoun...
Source: Current Treatment Options in Gastroenterology - Category: Gastroenterology Source Type: research
Activated macrophages play a key role in the development and maintenance of inflammatory diseases such as atherosclerosis, lupus, psoriasis, rheumatoid arthritis, ulcerative colitis, and many others. These activated macrophages, but not resting or quiescent macrophages highly upregulate folate receptor beta (FR- β). This differential expression of FR-β provides a mechanism to selectively deliver imaging and therapeutic agents utilizing folate as a targeting molecule. In an effort to determine whether inflammatory diseases can be targeted utilizing a folate-linked nanosize carrier, a PEG-coated liposome wa s prepa...
Source: Nanomedicine : Nanotechnology, Biology, and Medicine - Category: Nanotechnology Authors: Source Type: research
In conclusion, the clearance of tacrolimus in patients with autoimmune diseases was affected by the CYP3A5 genotype, as previously reported in organ transplant patients. The IMK ATP level may indicate the clinical response irrespective of tacrolimus concentration. PMID: 29375701 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
More News: Arthritis | Clinical Trials | Health | Inflammatory Bowel Disease | Pfizer | Rheumatoid Arthritis | Rheumatology | Ulcerative Colitis